Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NATPARA vs CHRONULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human parathyroid hormone (PTH 1-84) that binds to PTH1 receptors, increasing serum calcium by enhancing renal calcium reabsorption, intestinal calcium absorption, and bone resorption.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Hypoparathyroidism
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
Initial dose: 50 mcg subcutaneously once daily, titrate in 25 mcg increments every 2-4 weeks based on serum calcium and symptoms, maintenance dose range: 25-100 mcg once daily.
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
Terminal half-life approximately 2–5 minutes (subcutaneous); rapid clearance with clinical context: requires twice-daily dosing due to short half-life
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Metabolized in the liver via proteolytic cleavage, primarily by cathepsin D and other proteases.
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Primarily renal (≥95% as intact parathyroid hormone and metabolites); biliary/fecal elimination minimal (<5%)
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Approximately 55–60% bound to plasma proteins, primarily albumin
Negligible (<5%), primarily to albumin.
Approximately 0.1–0.2 L/kg; reflects limited extravascular distribution, primarily in plasma and interstitial space
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Subcutaneous: approximately 55% (relative to intravenous injection)
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
e GFR <30 m L/min/1.73 m2: initiate at 25 mcg daily, titrate cautiously; e GFR 30-59: no specific adjustment but monitor calcium; e GFR ≥60: no adjustment.
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
No formal studies; use with caution in severe hepatic impairment (Child-Pugh C) with increased monitoring.
No adjustment needed; used in hepatic encephalopathy at higher doses.
Not approved for patients <18 years; safety and efficacy not established.
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
No specific dose adjustment; consider age-related renal decline and lower starting dose (25 mcg).
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
None.
None.
Risk of osteosarcoma (increased with duration of use; avoid in patients with increased baseline risk),Digitalis toxicity,Hypocalcemia exacerbation upon discontinuation,Hypercalcemia and hypercalciuria requiring monitoring,Hypomagnesemia,Hypotension with rapid IV administration (not approved IV),Laboratory test interference (unlikely)
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Hypersensitivity to recombinant human PTH or any component,Pre-existing hypercalcemia,Metabolic bone diseases (e.g., Paget's disease),Radiation therapy to skeleton (increased osteosarcoma risk),Skeletal malignancies or bone metastases,Pediatric patients with open epiphyses
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
Avoid excessive dietary calcium intake beyond prescribed supplements as it may increase risk of hypercalcemia. High-oxalate foods (e.g., spinach, rhubarb, beets) may reduce calcium absorption; separate intake from calcium supplements by at least 2 hours. Foods high in phosphorus (e.g., dairy, nuts, whole grains) may affect calcium balance; maintain consistent intake. Do not consume high-dose vitamin D or vitamin A without medical supervision.
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
NATPARA (parathyroid hormone) is classified as Pregnancy Category C. In animal studies, parathyroid hormone has been associated with reduced fetal weight and skeletal abnormalities when administered during organogenesis. There are no adequate and well-controlled studies in pregnant women. The risk is likely highest during the first trimester due to skeletal development. Exposure in the second and third trimesters may affect fetal calcium homeostasis, but specific human data are lacking. Use only if potential benefit justifies potential risk to the fetus.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
It is unknown if parathyroid hormone is excreted in human milk. No human lactation studies are available. The molecular weight (4117 Da) suggests minimal excretion, but due to potential for adverse effects in the nursing infant, caution is advised. The M/P ratio is unknown. Consider the importance of the drug to the mother and decide whether to discontinue nursing or discontinue the drug.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
No specific dose adjustment guidelines exist for NATPARA in pregnancy. However, due to increased plasma volume and altered calcium metabolism during pregnancy, closer monitoring of serum calcium is required, and dose adjustments may be necessary to maintain target calcium levels within the normal range. Start with the lowest effective dose and titrate based on serum calcium response, typically every 2–4 weeks.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
NATPARA (parathyroid hormone) is a recombinant human PTH(1-84) used as an adjunct to calcium and vitamin D in hypoparathyroidism. Monitor serum calcium closely after initiation; adjust concomitant calcium and vitamin D doses to avoid hypercalcemia. Discontinue if serum calcium exceeds 12 mg/d L. Patients with renal impairment are at increased risk of hypercalcemia. Not recommended in patients with Paget's disease or skeletal metastases due to risk of osteosarcoma (based on animal studies). Store at 2-8°C; do not freeze. Administer via subcutaneous injection into the thigh using the provided pen device.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
NATPARA is used to increase low calcium levels by replacing parathyroid hormone.,You must take calcium and vitamin D supplements as directed; do not stop them unless instructed.,Inject NATPARA into the thigh exactly as prescribed, using a new needle each time.,Store the pen in the refrigerator at 2-8°C; do not freeze or shake.,Common side effects include nausea, diarrhea, and injection site reactions.,Report symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid taking thiazide diuretics (e.g., hydrochlorothiazide) without doctor approval as they can raise calcium levels.,Do not use if you have Paget's disease, bone cancer, or have had radiation to bones.,Keep all appointments for blood tests to monitor calcium and kidney function.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NATPARA vs CHRONULAC, answered by our medical review team.
NATPARA is a Parathyroid Hormone Analog that works by Recombinant human parathyroid hormone (PTH 1-84) that binds to PTH1 receptors, increasing serum calcium by enhancing renal calcium reabsorption, intestinal calcium absorption, and bone resorption.. CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NATPARA and CHRONULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NATPARA is: Initial dose: 50 mcg subcutaneously once daily, titrate in 25 mcg increments every 2-4 weeks based on serum calcium and symptoms, maintenance dose range: 25-100 mcg once daily.. The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NATPARA and CHRONULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NATPARA is classified as Category C. NATPARA (parathyroid hormone) is classified as Pregnancy Category C. In animal studies, parathyroid hormone has been associated with reduced fetal weight and skeletal abnormalities. CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.